checkAd

     120  0 Kommentare MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte - Seite 3 

    CONTACT: Contacts:

Jim Karrels, Senior Vice President, CFO
1-301-251-5172, info@macrogenics.com


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte - Seite 3 $15 Million milestone triggered by initiation of Phase 3 clinical trial in NSCLC by Incyte ROCKVILLE, MD, Sept. 21, 2020 (GLOBE NEWSWIRE) - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and …